A Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs JNJ 64304500 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 27 Sep 2017 Status changed from recruiting to completed.
- 02 Feb 2017 Status changed from not yet recruiting to recruiting.
- 20 Jan 2017 Planned initiation date changed from 1 Jan 2017 to 1 Dec 2016.